Lusutrombopag

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lusutrombopag
Lusutrombopag.svg
Clinical data
Trade namesMulpleta
Routes of
administration
Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC29H32Cl2N2O5S
Molar mass591.54 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)

Lusutrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. It is being manufactured and marketed in Japan by Shionogi under the trade name Mulpleta.[1][2][3] It was approved by the FDA in July 2018.[4]

References[edit]

  1. ^ Shionogi Receives Marketing and Manufacturing Approval in Japan for MULPLETA® Tablets 3mg for Improvement of Thrombocytopenia, September 28, 2015
  2. ^ Shionogi Launches MULPLETA® Tablets 3mg In Japan for Improvement of Thrombocytopenia
  3. ^ Lusutrombopag (MULPLETA) for severe thrombocytopenia in patients with chronic liver disease undergoing an elective invasive procedure
  4. ^ "FDA approves lusutrombopag for thrombocytopenia in adults with chronic liver disease". Food and Drug Administration. July 31, 2018.